Closing the gap between national approval and local adoption.
As clinicians we stood at the bedside knowing the answer existed somewhere, in a protocol, a formulary, a guideline, a colleague's head, and we still couldn't reach it in the moment it mattered.
That gap between what medicine knows and what a clinician can act on at the point of care is the problem Eolas was built to close. We're not guessing at it. We lived it.
We exist to transform how knowledge reaches the point of care.
The national update is the trigger. The local version is what's read at the moment of decision.
Click here to download the full industry insights reportSource: Eolas Medical platform data, 12 months to August 2026. The Last Mile of Guideline Adoption, Eolas Medical Industry Insight.
From national update to local guideline in days, not months.
Clinicians using Ask Eolas achieved 100% prescribing accuracy versus 47% with standard practice, with a number needed to treat of 1.9.
Waldock W.J., Gilchrist M., Ashrafian H., Darzi A. & Dean Franklin B.
npj Antimicrobials and Resistance 4, 16 (2026)
Read the paper · doi:10.1038/s44259-026-00187-7Diagnostic and referral pathways in place, so eligible patients are identified before day one.
National changes surfaced to local decision-makers, with guidance drafted, approved and live quickly.
The right information to the right specialty and grade, in the workflow they already use.
Underpinning all three: guidance clinicians can find in seconds, at the point of care.
Three measures, tracked from day one, that show where your launch is gaining ground and where to act next.
Illustrative curve.
Start with one product and one NICE decision. In 30 minutes we'll show you where local adoption is stuck, and what closing that gap is worth.
Better Knowledge. Safer Care.
